| DBVT Stock | | | USD 0.50 0.03 6.38% |
Director
Ms. Lucie Mondoulet is the Director of Research of DBV Technologies SA. She graduated in Biochemical and Food Engineering from Institut National des Sciences Appliquees in Toulouse and then specialized in the field of food allergy. She graduated with a Doctorate degree from INRA in the immunology and food allergy unit, where she studied the biochemical composition of peanut allergens and related treatments. She then specialized with postdoctorate research at the CNRS in Paris within the allergy and environment department, where she was in charge of pollen allergens purification and studied the immunologic response of allergic patients. She then joined DBV Technologies SA as a Research Engineer and first set up preclinical models in the field of pharmacology before taking charge of the coordination of the research team.
| Address | 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset
(ROA) of
(0.4625) % which means that it has lost $0.4625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.0311) %, meaning that it created substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.39 in 2024.
Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, DBV Technologies'
Liabilities And Stockholders Equity is comparatively stable compared to the past year.
Change To Liabilities is likely to gain to about 3.3
M in 2024, whereas
Total Current Liabilities is likely to drop slightly above 31
M in 2024.
DBV Technologies currently holds 6.55
M in liabilities with Debt to Equity
(D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 8.37, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about DBV Technologies' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | DIRECTOR Age |
| Raquel MS | HCW Biologics | N/A |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. DBV Technologies (DBVT) is traded on NASDAQ Exchange in USA. It is located in 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 and employs 108 people. DBV Technologies is listed under Biotechnology category by Fama And French industry classification.
Management Performance
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Becker, VP Communications | |
| Sbastien Robitaille, Chief Officer | |
| Wence Agbotounou, Chief Clinical Trial Officer | |
| Caroline Daniere, Chief Staff | |
| Daniel Tass, CEO Director | |
| Edward MBA, Senior America | |
| Alan Kerr, Senior Affairs | |
| Pascal Wotling, Chief Officer | |
| Pharis Mohideen, Chief Officer | |
| Virginie MBA, CFO Officer | |
| Katie Matthews, Investor Officer | |
| Lucie Mondoulet, Director of Research Department | |
| Anne Pollak, Head Relations | |
| Michele Robertson, Chief Officer | |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to
measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to
predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.